The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Direct-acting antiviral drugs (DAA) regimen improve the SVR rate. However, adverse effects often lead to therapy interruption. This underlines the importance to find some predictive parameters of response in order to consider the possibility of a shorter time of antiviral treatment in the appearance of adverse effects without affecting the success of the therapy. Objectives: We aimed to examine the HCVAg kinetics in the early phase of treatment and its predictive value of SVR in patients undergoing TPV/Peg-IFN/RBV treatment. Study design: Twenty-three patients infected by HCV genotype 1 (1a n= 11; 1b n= 12) were included in this prospective study. Results: At baseline the median Log of HCVAg concentration in RVR and EVR patients were 3.15. fmol/L and 3.45. fmol/L, respectively with no significant differences. The baseline median HCV-RNA to HCVAg ratio was 233.77, this ratio was significantly lower when measured on day 1 (27.52) and on day 6 (24.84) (p

Original languageEnglish
Pages (from-to)68-73
Number of pages6
JournalJournal of Clinical Virology
Volume69
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Ribavirin
Interferons
Genotype
Antigens
Infection
Antiviral Agents
Therapeutics
telaprevir
Prospective Studies
RNA

Keywords

  • EVRearly virological response
  • HCVcore antigen
  • Hepatitis C virus
  • RVRrapid virological response
  • SVRsustained virological response
  • Telaprevir

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

@article{ad8adf6c6613443cb07e1b1b285e544e,
title = "The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection",
abstract = "Background: Direct-acting antiviral drugs (DAA) regimen improve the SVR rate. However, adverse effects often lead to therapy interruption. This underlines the importance to find some predictive parameters of response in order to consider the possibility of a shorter time of antiviral treatment in the appearance of adverse effects without affecting the success of the therapy. Objectives: We aimed to examine the HCVAg kinetics in the early phase of treatment and its predictive value of SVR in patients undergoing TPV/Peg-IFN/RBV treatment. Study design: Twenty-three patients infected by HCV genotype 1 (1a n= 11; 1b n= 12) were included in this prospective study. Results: At baseline the median Log of HCVAg concentration in RVR and EVR patients were 3.15. fmol/L and 3.45. fmol/L, respectively with no significant differences. The baseline median HCV-RNA to HCVAg ratio was 233.77, this ratio was significantly lower when measured on day 1 (27.52) and on day 6 (24.84) (p",
keywords = "EVRearly virological response, HCVcore antigen, Hepatitis C virus, RVRrapid virological response, SVRsustained virological response, Telaprevir",
author = "Garbuglia, {Anna Rosa} and Raffaella Lionetti and Daniele Lapa and Chiara Taibi and Ubaldo Visco-Comandini and Marzia Montalbano and Gianpiero D'Offizi and Filippo Castiglione and Capobianchi, {Maria Rosaria} and Paola Paci",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.jcv.2015.06.002",
language = "English",
volume = "69",
pages = "68--73",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",

}

TY - JOUR

T1 - The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

AU - Garbuglia, Anna Rosa

AU - Lionetti, Raffaella

AU - Lapa, Daniele

AU - Taibi, Chiara

AU - Visco-Comandini, Ubaldo

AU - Montalbano, Marzia

AU - D'Offizi, Gianpiero

AU - Castiglione, Filippo

AU - Capobianchi, Maria Rosaria

AU - Paci, Paola

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: Direct-acting antiviral drugs (DAA) regimen improve the SVR rate. However, adverse effects often lead to therapy interruption. This underlines the importance to find some predictive parameters of response in order to consider the possibility of a shorter time of antiviral treatment in the appearance of adverse effects without affecting the success of the therapy. Objectives: We aimed to examine the HCVAg kinetics in the early phase of treatment and its predictive value of SVR in patients undergoing TPV/Peg-IFN/RBV treatment. Study design: Twenty-three patients infected by HCV genotype 1 (1a n= 11; 1b n= 12) were included in this prospective study. Results: At baseline the median Log of HCVAg concentration in RVR and EVR patients were 3.15. fmol/L and 3.45. fmol/L, respectively with no significant differences. The baseline median HCV-RNA to HCVAg ratio was 233.77, this ratio was significantly lower when measured on day 1 (27.52) and on day 6 (24.84) (p

AB - Background: Direct-acting antiviral drugs (DAA) regimen improve the SVR rate. However, adverse effects often lead to therapy interruption. This underlines the importance to find some predictive parameters of response in order to consider the possibility of a shorter time of antiviral treatment in the appearance of adverse effects without affecting the success of the therapy. Objectives: We aimed to examine the HCVAg kinetics in the early phase of treatment and its predictive value of SVR in patients undergoing TPV/Peg-IFN/RBV treatment. Study design: Twenty-three patients infected by HCV genotype 1 (1a n= 11; 1b n= 12) were included in this prospective study. Results: At baseline the median Log of HCVAg concentration in RVR and EVR patients were 3.15. fmol/L and 3.45. fmol/L, respectively with no significant differences. The baseline median HCV-RNA to HCVAg ratio was 233.77, this ratio was significantly lower when measured on day 1 (27.52) and on day 6 (24.84) (p

KW - EVRearly virological response

KW - HCVcore antigen

KW - Hepatitis C virus

KW - RVRrapid virological response

KW - SVRsustained virological response

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84937819902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937819902&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2015.06.002

DO - 10.1016/j.jcv.2015.06.002

M3 - Article

C2 - 26209382

AN - SCOPUS:84937819902

VL - 69

SP - 68

EP - 73

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

ER -